Funding Received
$7.4 Million in 2 Rounds from 2 Investors
Most Recent Funding
$5.7 Million Venture on December 18, 2012
Southport, CT
Thetis Pharmaceuticals develops novel prescription drugs for the treatment of diabetes, hypertriglyceridemia and dyslipidemia.

Company Details

None found in CrunchBase

Thetis Pharmaceuticals LLC is a bio-pharmaceutical company creating innovative chemistry and regulatory strategies in the development of prescription drugs in the Omega-3 arena.

The Company has three differentiated and IP-protected drug candidates at varying stages of development: TP-101 for the treatment of type 2 diabetes, TP-943 for the treatment of hypertriglyceridemia and mixed dyslipidemia, and TP-721 for the prevention and treatment of atrial fibrillation.

The key innovation underlying Thetis’ drug portfolio revolves around pharmaceuticalizing Omega-3 poly- unsaturated fatty acids into solid, water-soluble, new chemical entities (NCEs). This technology creates NCEs that instantaneously dissociate in aqueous media to deliver known entities in either a superior or targeted manner. Since the delivered entities are known drugs with excellent safety profiles, the Company expects to bypass many pre-clinical and clinical safety requirements and seek expedited registration in the U.S. Furthermore these novel chemical compounds have excellent prospects for superiority over existing Omega-3 drugs.

Funding Rounds (2) - $7.4M


Investors (2)

  • 1aa3ff9ff75842b011a909e1f518ae84

    Stonehenge Capital

    Stonehenge Capital Company is a national specialty finance company, with expertise in private...
  • 0a1fc8ca9464a6026e63bfd6586fdf01

    Connecticut Innovations

    Connecticut Innovations provides strategic capital and operational insight to to companies in...

Offices/Locations (1)

  • Office

    167 Old Post Road

    Southport, CT 06890